Purple biotech reports positive interim and preliminary results from nt219 phase 1/2 study in r/m head & neck cancer

Rehovot, israel, oct. 03, 2023 (globe newswire) -- purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,  provides clinical updates from its dose escalation portion of the phase 1/2 study of nt219, a first in class  dual inhibitor of insulin receptor substrate (irs) 1/2 and signal transducer and activator of transcription 3 (stat3) and provides its outlook for planning the next clinical development steps with nt219 for second-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head & neck (r/m scchn).
PPBT Ratings Summary
PPBT Quant Ranking